SOPHiA GENETICS S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SOPH research report →
Range $9 – $14
Price Chart
About the company
SOPHiA GENETICS S. A. operates as a specialized company within the healthcare technology sector.
- CEO
- Ross Muken
- IPO
- 2021
- Employees
- 415
- HQ
- Rolle, VD, CH
Get TickerSpark's AI analysis on SOPH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $530.35M
- P/E
- -5.72
- Fwd P/E
- 14.66
- PEG
- -2.60
- P/S
- 5.83
- P/B
- 7.79
- EV/EBITDA
- -7.52
- Div Yield
- 0.00%
- Gross Margin
- 66.43%
- Op Margin
- -80.47%
- Net Margin
- -89.18%
- ROE
- -132.79%
- ROIC
- -55.25%
Latest fiscal year · YoY change
- Revenue
- $77.27M+18.6%
- Gross Profit
- $47.81M+8.8%
- Op Income
- $-70,925,000
- Net Income
- $-78,999,000-26.4%
- EPS
- $-1.17-23.2%
- OCF Growth
- +11.2%
- FCF Growth
- +24.3%
- 52W High
- $8.98
- 52W Low
- $3.91
- 50D MA
- $7.60
- 200D MA
- $6.09
- Beta
- 0.95
- RSI (14)
- 41
- Avg Volume
- 672.43K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
SOPHiA GENETICS posted 25% revenue growth in Q3, improved adjusted EBITDA loss, and raised full-year revenue outlook to the top end of guidance despite FX headwinds.· November 3, 2026
- Q3 revenue rose 25% year over year to $24.3 million, with record analysis volume of 118,000, up 19%.
- Adjusted EBITDA loss improved to $6.1 million from an $8.8 million loss a year ago, and management said it expects further improvement in Q4.
- U.S. growth remained the key driver, with U.S. revenue up 41% and North America up 45%; management said recent wins should ramp into Q4 and 2027.
- Liquid Biopsy accelerated sharply, with 4,200 analyses, up more than 100% year over year and 41% sequentially, as more institutions implement MSK-ACCESS.
- Full-year 2026 revenue is now expected at the upper end of the prior $94 million to $96 million range; adjusted EBITDA loss guidance stays at $29 million to $32 million.
Q3 2026 revenue was $24.3 million, versus $19.5 million in Q3 2025, up 25% year over year, or 26% on a constant-currency basis. Gross profit was $15.9 million versus $12.9 million a year ago, and gross margin was 65.7% compared with 66.3%. Adjusted gross profit was $17.6 million, with adjusted gross margin of 72.8% versus 73.1% last year. Adjusted EBITDA loss improved to $6.1 million from $8.8 million, and operating loss was $17.8 million versus $17.9 million. Cash at quarter-end was $94 million. For full-year 2026, management now expects revenue at the upper end of the previously issued $94 million to $96 million range and reaffirmed adjusted EBITDA loss guidance of $29 million to $32 million.
Ross Muken framed the quarter as evidence that SOPHiA is entering a stronger growth phase, driven by U.S. expansion, Liquid Biopsy adoption, and rising BioPharma demand. He emphasized that the platform’s network effects and data scale are creating a differentiated “clinical intelligence” offering, and he repeatedly pointed to favorable U.S. market dynamics such as improving reimbursement and lower sequencing costs. His tone was confident and optimistic, but he also stressed that the company intends to keep growth disciplined and sustainable.
George Cardoza highlighted broad-based revenue and volume strength, including 45% North America growth, 33% Asia Pacific growth, and strong application performance across Solid Tumor, HemOnc, Rare Disorders, and Liquid Biopsy. He noted that adjusted OpEx was $23.7 million, roughly flat year over year, with R&D down 18% and G&A roughly flat on an adjusted basis, underscoring cost discipline. He also pointed to a $94 million cash balance, reiterated confidence in reaching positive adjusted EBITDA in the second half of 2027, and said the full-year revenue outlook was lifted despite a foreign exchange headwind that could weigh on Q4 reported revenue.
Analysts focused on whether current U.S. growth rates in Solid Tumor, HemOnc, and Rare Disorders are sustainable into 2027; management said momentum should continue, with Solid Tumor possibly accelerating and heme growth likely to sustain. Questions also centered on BioPharma execution and whether the team can keep meeting timelines while taking on more work; management said the AstraZeneca CDx programs are still early, but the funnel is strong and BioPharma is becoming a meaningful accelerator. On backlog and implementation timing, management said the backlog remains high and that 95% of 2027 growth is already covered or signed, while also confirming that FX is a headwind to reported Q4 revenue and that gross margin should improve gradually over time.
The call showed strong commercial momentum across multiple growth engines: U.S. growth, Liquid Biopsy, and BioPharma. Management also said the backlog is unusually full and that 95% of 2027 growth is already covered or signed, which gives visibility into next year. At the same time, the company is showing operating leverage, improving adjusted EBITDA while keeping OpEx relatively controlled.
Management flagged foreign exchange as a near-term headwind, especially for Q4 reported revenue, even though underlying demand remains strong. Liquid Biopsy is still early in ex-U.S. markets and requires more education, evidence generation, and reimbursement work, which means adoption may take time. The company is also still loss-making, and while it expects progress, positive adjusted EBITDA is not expected until the second half of 2027.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 77.7%
- Shares Outstanding
- 85.13M
- Float Shares
- 66.17M
of shares held by institutions
75 13F filers
Buy/sell ratio 0.11. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Generation Investment Management Llp | 6.79M | 0 |
| Royce & Associates LP | 3.89M | ▲ 506.01K |
| Akre Capital Management LLC | 3.72M | 0 |
| Ameriprise Financial Inc | 2.22M | ▲ 2.22M |
| Principal Financial Group Inc | 2.15M | ▼ 209.74K |
| Awm Investment Company, Inc. | 1.76M | ▲ 64.20K |
| Aigh Capital Management LLC | 1.69M | ▼ 2.26M |
| Soleus Capital Management, L.P. | 1.56M | ▼ 285.00K |
| Silvercrest Asset Management Group LLC | 1.43M | ▲ 1.43M |
| Alta Wealth Advisors LLC | 1.26M | ▼ 150.00K |
| Next Century Growth Investors LLC | 1.05M | ▲ 1.05M |
| Kennedy Capital Management LLC | 917.98K | ▼ 9.82K |
Held by 10 ETFs
Biggest fund positions in SOPH by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Van Well Daan | sell | 1,224 |
| Nov 13, 26 | Xu Zhenyu | sell | 4,000 |
| Nov 12, 26 | Menu Philippe | sell | 5,000 |
| Nov 10, 26 | HIBBS KATHY L | sell | 6,250 |
| Nov 10, 26 | Camblong Jurgi | sell | 8,500 |
| Nov 9, 26 | Van Well Daan | sell | 1,411 |
| Nov 6, 26 | CARDOZA GEORGE | buy | 20,000 |
| Nov 6, 26 | Muken Ross | buy | 20,000 |
| Oct 12, 26 | Menu Philippe | sell | 5,000 |
| Oct 13, 26 | Xu Zhenyu | sell | 4,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SOPH coverage
Recent articles, reports, and earnings notes.
No research on SOPH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SOPH report →SOPHiA: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 16
SOPHiA GENETICS SA (SOPH) Presents at 2026 UBS Global Healthcare Conference Transcript
seekingalpha.com · Nov 9
SOPHiA GENETICS Q3 Earnings Call Highlights
defenseworld.net · Nov 5
SOPHiA GENETICS SA (SOPH) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 3
SOPHiA GENETICS Q3 Earnings Call Highlights
marketbeat.com · Nov 3
SOPHiA GENETICS SA (SOPH) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 3
SOPHiA GENETICS Reports Third Quarter 2026 Results
prnewswire.com · Nov 3
SOPHiA GENETICS to Announce Financial Results for Third Quarter 2026 on November 3, 2026
prnewswire.com · Oct 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.